Introducing Lonza’s AAV suspension transient transfection platform to de-risk your path to clinic

Adeno associated viral vector (AAV) is the delivery vehicle of choice for potentially curative in vivo gene therapy. Following a couple of landmark approvals, this field has experienced accelerated pipeline growth and investor interest in the past five years. Currently AAV therapies are predominantly targeting rare genetic disorders for which the patient population is often limited. As a result, drug developers feel immense pressure to be first to market to commercialize their therapies.

In this Webinar, Lonza CGT will focus on a robust, streamlined platform process for fast production of AAV using Lonza’s clonal suspension HEK293 cell line, proprietary plasmids to ensure high productivity and in process analytics enabling enhanced full to empty capsid ratio. We will further discuss Lonza’s approach for building reliable, de-risked path to clinic to avoid unforeseen costs and compliance-related delays.

Speed to clinic with a de-risked, robust, scalable platform process for AAV production
High AAV productivity and yield with Lonza’s proprietary plasmids (Rep/cap + pHelper) and clonal HEK293 cell line
Full/empty analytics enabling USP and DSP optimization at early stages/small scale
Pre-qualified platform assays

Dr Suparna Sanyal

Head of Viral Vectors Commercial Development, Lonza Pharma & Biotech

Dr Suparna Sanyal is Head of Viral Vectors Commercial Development at Lonza Cell and Gene Technologies where she works with their global business, R&D and operations teams to enable strategic development and commercialization of their viral vector manufacturing services. Suparna’s background is in Neuroscience and she earned her PhD from the University of Toronto in Neuropharmacology. She has over 15 years of R&D, drug discovery, CDMO and cell and gene therapy experience.